A Phase 3 interventional study of Recombinant single-chain factor VIII (rVIII-SingleChain) in Congenital Hemophilia A, sponsored by CSL Behring. Completed at 20 sites in China. Open to male participants aged 0 Days to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hemophilia A by CSL Limited — none open to participants now, none under way, none of them phase 3. Hemophilia A · CSL Limited.
Among the 14 studies in Hemophilia A by CSL Limited, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 3, and was the 14th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →None of the 14 studies in Hemophilia A by CSL Limited is open now. The open studies under Hemophilia A, anywhere →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 0 Days to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2025.
This study's enrollment of 62 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 62 across the 11 interventional studies, 62 across the 3 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hemophilia A by CSL Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than [\<] 1%).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rVIII-SingleChain as an intravenous (IV) infusion for a minimum of 50 exposure days (EDs).
Biological: Recombinant single-chain factor VIII (rVIII-SingleChain)
Lyophilized powder for solution for intravenous injection
Also known as: CSL627
Incremental Recovery (IR) of rVIII-SingleChain
Time frame: Before, and at 30 minutes after the end of, rVIII-SingleChain administration on Day 1
Maximum Concentration (Cmax) of rVIII-SingleChain
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
Area Under the Plasma Concentration Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of rVIII-SingleChain
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUC0-inf) of rVIII-SingleChain
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
Half-life (t1/2) of rVIII-SingleChain
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
Clearance (Cl) of rVIII-SingleChain
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
Annualized Spontaneous Bleeding Rate (AsBR)
AsBR for treated bleeding episodes
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Number of participants who develop FVIII inhibitors
Time frame: During routine rVIII-SingleChain prophylaxis dosing, up to 29 weeks after rVIII-SingleChain administration.
Time to reach maximum concentration (Tmax) of rVIII-SingleChain
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
Last Concentration (Clast) of rVIII-SingleChain
Last observed quantifiable plasma concentration
Time frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
IR (participants ≥ 12 years of age) of rVIII-SingleChain (Repeat pharmacokinetic [PK])
Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28
Cmax (participants ≥ 12 years of age) of rVIII-SingleChain (Repeat PK)
Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28
AUC0-last of rVIII-SingleChain (Repeat PK)
Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28
AUC0-inf of rVIII-SingleChain (Repeat PK)
Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28
t1/2 of rVIII-SingleChain (participants ≥ 12 years of age) (Repeat PK)
Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28
Cl of rVIII-SingleChain (participants ≥ 12 years of age) (Repeat PK)
Time frame: Before, and at up to 72 hours after the end of, rVIII-SingleChain infusion at Week 28
Annualized Bleeding Rate (ABR)
Total ABR for treated, untreated, and both treated and untreated bleeding episodes (spontaneous, traumatic, and unknown cause)
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Hemostatic Efficacy for Major and Nonmajor Bleeding Episodes
The investigator will rate the efficacy of the rVIII-SingleChain treatment for major and nonmajor bleeding episodes based on a hemostatic efficacy four point rating scale of "excellent, good, moderate or no efficacy".
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Consumption of rVIII-SingleChain - number of infusions (doses)
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Consumption of rVIII-SingleChain - IU/kg per participant per month
rVIII-SingleChain consumption (IU/kg) per participant per month, for the weekly regimen, on-demand treatment, and total treatment.
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Consumption of rVIII-SingleChain - IU/kg per participant per year
rVIII-SingleChain consumption (IU/kg) per participant per year, for the weekly regimen, on-demand treatment, and total treatment.
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Number of bleeding episodes requiring rVIII-SingleChain to achieve hemostasis
Number of bleeding episodes requiring 1, \<= 2, or \> 2 infusions (doses) of rVIII-SingleChain to achieve hemostasis
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Percentage of bleeding episodes requiring rVIII-SingleChain to achieve hemostasis
Percentage of bleeding episodes requiring 1, \<= 2, or \> 2 infusions (doses) of rVIII-SingleChain to achieve hemostasis
Time frame: Up to 29 weeks after rVIII-SingleChain administration
Number of participants who develop noninhibitory antibodies against rVIII-SingleChain
Time frame: Before, and up to 29 weeks after, rVIII-SingleChain administration
Number of participants who develop antibodies against Chinese hamster ovary host cell protein
Time frame: Before, and up to 29 weeks after, rVIII-SingleChain administration
Number of participants with Treatment-emergent Adverse Events (TEAEs), including related TEAEs, and serious adverse events (SAEs)
Time frame: Up to 33 weeks after rVIII-SingleChain administration
Percentage of participants with TEAEs, including related TEAEs, and serious adverse events (SAEs)
Time frame: Up to 33 weeks after rVIII-SingleChain administration
Number of TEAEs (events)
Time frame: Up to 33 weeks after rVIII-SingleChain administration
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (i.e., FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Sep 2026, 20 months.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 20 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lonoctocog alfa